

## Take Home Messages: Achieving Tomorrow's Outcomes Through Education Today

- Be very cautious when considering therapy of SMM 2,20,20 is an oversimplification
- Daratumumab has become an accepted standard for NDMM induction
- Trials underway for 2 drug maintenance therapy for high risk subgroups
- Venetoclax is active in amyloidosis
- 3 trials underway to dissolve amyloid deposits in vivo